Details for Patent: 12,013,403
✉ Email this page to a colleague
Which drugs does patent 12,013,403 protect, and when does it expire?
Patent 12,013,403 protects SPINRAZA and is included in one NDA.
This patent has five patent family members in four countries.
Recent additions to Drugs Protected by US Patent 12,013,403
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1941 | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY | |||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1942 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA | |||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1943 | TREATMENT OF SPINAL MUSCULAR ATROPHY | |||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1944 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,013,403
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY | ⤷ Sign Up | ||||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA | ⤷ Sign Up | ||||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SPINAL MUSCULAR ATROPHY | ⤷ Sign Up | ||||
| Biogen Idec | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,013,403
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112017004056 | ⤷ Sign Up | |||
| Chile | 2017000594 | ⤷ Sign Up | |||
| Chile | 2019000447 | ⤷ Sign Up | |||
| Colombia | 2017002400 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
